The effect of 6-week treatment with escitalopram on CCK-4 challenge: A placebo-controlled study in CCK-4-sensitive healthy volunteers

European Neuropsychopharmacology

Volumn 23, Issue 7, 2013, Pages 645-652

  Tõru, Innar ^a   Maron, Eduard ^a,b   Raag, Mait ^a   Vasar, Veiko ^a   Nutt, David J ^b   Shlik, Jakov ^c  

^a UNIVERSITY OF TARTU   (Estonia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

CCK 4; Healthy volunteers; Panic attack; Serotonin; SSRI

Indexed keywords

ESCITALOPRAM; PLACEBO; TETRAGASTRIN;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; PANIC; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; CITALOPRAM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; POLYMORPHISM, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TETRAGASTRIN;

EID: 84878880431     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.08.011     Document Type: Article

References (52)

1. Aluoja A., Shlik J., Vasar V., Kingissepp P.H., Jagomagi K., Vasar E., Bradwejn J. Emotional and cognitive factors associated with response to CCK-4 in healthy volunteers. Psychiatry Res. 1997, 66:59-67.
2. Aluoja A., Shlik J., Vasar V., Luuk K., Leinsalu M. Development and psychometric properties of the Emotional State Questionnaire, a self-report questionnaire for depression and anxiety. Nord. J. Psychiatry 1999, 53:443-449.
3. Argyropoulos S.V., Wilson S.J., Nutt D.J. The effects of antidepressant drugs and 5-HT1A agonists on human sleep. Serotonin and Sleep: Molecular Functional and Clinical Aspects 2008, 569-585. Birkhäuser Verlag Ag, Basel, Switzerland. J.M. Monti, S.R. Pandi-Perumal, B.L. Jacobs, D.J. Nutt (Eds.).
4. Attenburrow M.J., Mitter P.R., Whale R., Terao T., Cowen P.J. Low-dose citalopram as a 5-HT neuroendocrine probe. Psychopharmacology 2001, 155:323-326.
5. Bell C.J., Nutt D.J. Serotonin and panic. Br. J. Psychiatry 1998, 172:465-471.
6. Bell C., Forshall S., Adrover M., Nash J., Hood S., Argyropoulos S., Rich A., Nutt D.J. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J. Psychopharmacol. 2002, 16:5-14.
7. Bhagwagar Z., Hafizi S., Cowen P.J. Acute citalopram administration produces correlated increases in plasma and salivary cortisol. Psychopharmacology 2002, 163:118-120.
8. Bond A.J., Lader M.H. The use of analogue scales in rating subjective feelings. Br. J. Psychol. 1974, 47:211-218.
9. Bradwejn J., Koszycki D., Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioural findings. Arch. Gen. Psychiatry 1991, 48:603-607.
10. Bradwejn J., Koszycki D., Payeur R., Bourin M., Borthwick H. Study of the replication of action of cholecystokinin in panic disorders. Am. J. Psychiatry 1992, 92:962-964.
11. Bradwejn J., Koszycki D. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am. J. Psychiatry 1994, 151:261-263.
12. Bradwejn J., Koszycki D. The cholecystokinin hypothesis of anxiety and panic disorder. Ann. NY Acad. Sci. 1994, 713:273-282.
13. Bradwejn J., Koszycki D. Cholecystokinin and panic disorder: past and future clinical research strategies. Scand. J. Clin. Lab. Invest. Suppl. 2001, 234:19-27.
14. Deakin J.F.W., Graeff F.G. 5-HT and mechanisms of defence. J. Psychopharmacol. 1991, 5:305-315.
15. Depot M., Caille G., Mukherjee J., Katzman M.A., Cadieux A., Bradwejn J. Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans. Neuropsychopharmacology 1999, 20:177-187.
16. Djordjevic S., Kovacevic I., Miljkovic B., Vuksanovic J., Pokrajac M. Liquid chromatographic-mass spectrometric method for the determination of fluoxetine and norfluoxetine in human plasma: application to clinical study. Il Farmaco 2005, 60:345-349.
17. Eser D., Schüle C., Baghai T., Floesser A., Krebs-Brown A., Enunwa M., de la Motte S., Engel R., Kucher K., Rupprecht R. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteer within a proof-of-concept study. Psychopharmacology 2007, 192:479-487.
18. Eser D., Wenninger S., Baghai T., Schüle C., Rupprecht R. Impact of state and trait anxiety on the panic response to CCK-4. J. Neural. Transm. 2008, 115:917-920.
19. Hamilton M. Diagnosis and rating of anxiety. Br. J. Psychiatry (Special publication) 1969, 76-79.
20. Hinkelmann K., Yassouridis A., Mass R., Tenge H., Kellner M., Jahn H., Wiedemann K., Wolf K. CCK-4: Psychophysiological conditioning elicits features of spontaneous panic attacks. J. Psychiatr. Res. 2010, 44:1148-1153.
21. Kasper S., Resinger E. Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors. Eur. Neuropsychopharmacol. 2001, 11:307-321.
22. Kellner M., Muhtz C., Demiralay C., Husemann J., Koelsch W., Yassouridis A., Wiedemann K. The selective serotonin re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype. J. Psychiatr. Res. 2009, 43:642-648.
23. Koszycki D., Zacharko R.M., Le Melledo J.M., Young S.N., Bradwejn J. Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Biol. Psychiatry 1996, 40:648-655.
24. Kronenberg G., Berger P., Tauber R.F., Bandelow B., Henkel V., Heuser I. Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. Pharmacopsychiatry 2005, 38:24-29.
25. Le Melledo J-M., Merani S., Kosycki D., Palmour R., Gutkowska Y., Bellavance F., Steinberg S.I., Bichet D.G., Bradwejn J. Influences of the menstrual cycle and premenstrual dysphoric disorder on the response to CCK-4. Neuropsychopharmacology 1999, 20:81-91.
26. Maron E., Tõru I., Vasar V., Shlik J. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers. J. Psychopharmacol. 2004, 18:194-199.
27. Maron E., Tasa G., Tõru I., Lang A., Vasar V., Shlik J. Association between Seotonin-related Genetic Polymorphisms and CCK-4-induced Panic Attacks with or without 5-hydroxytryptophan Pretreatment in Healthy Volunteers. World J. Biol. Psychiatry 2004, 5:149-154.
28. Maron E., Kuikka J.T., Shlik J., Vasar V., Vanninen E., Tiihonen J. Reduced brain serotonin transporter binding in patients with panic disorder. Psychiatry Res. 2004, 132:173-181.
29. Maron E., Shlik J. Serotonin function in panic disorder: important, but why?. Neuropsychopharmacology 2006, 31:1-11.
30. Maron E., Tõru I., Tasa G., Must A., Toover E., Lang A., Vasar V., Shlik J. Association testing of panic disorder candidate genes using CCK-4 challenge in healthy volunteers. Neuroscience Letters 2008, 446:88-92.
31. Maron E., Hettema J.M., Shlik J. Advances in molecular genetics of panic Disorder. Mol. Psychiatry 2010, 15:681-701.
32. Maron E., Toru I., Hirvonen J., Tuominen L., Lumme V., Vasar V., Shlik J., Nutt D.J., Helin S., Någren K., Tiihonen J., Hietala J. Gender differences in brain serotonin transporter availability in panic disorder. J. Psychopharmacol. 2011, 25:952-959.
33. Nash J.R., Sargent P.A., Rabiner E.A., Hood S.D., Argyropoulos S.V., Potokar J.P., Grasby P.M., Nutt D.J. Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. Br. J. Psychiatry 2008, 193:229-234.
34. Neumeister A., Bain E., Nugent A.C., Carson R.E., Bonne O., Luckenbaugh D.A., Eckelman W., Herscowitch P., Charney D.S., Drevets W.C. Reduced serotonin type 1A receptor binding in panic disorder. J. Neurosci. 2004, 24:589-591.
35. Otto M.W., Tuby K.S., Gould R.A., McLean R.Y., Pollack M.H. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am. J. Psychiatry 2001, 158:1989-1992.
36. 2 reactivity and serotonin transporter gene regulatory region polymorphism in panic disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004, 129B:41-43.
37. Perna G., Favaron E., Di Bella D., Bussi R., Bellodi L. Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology 2005, 30:2230-2235.
38. Radu D., Ahlin A., Svanborg P., Lindefors N. Pentagastrin test for anxiety-psychophysiology and personality. Psychopharmacology 2003, 166:139-145.
39. Raiteri M., Paudice P., Vallebuona F. Release of cholecystokinin in the central nervous system. Neurochem. Int. 1993, 22:519-527.
40. Reis M., Aamo T., Spigset O., Ahlner J. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther. Drug Monit. 2007, 31:42-56.
41. Rosen, A., Franck, J., Brodin, E., 1995. Effects of acute systemic treatment with the 5-HT-uptake blocker alaprocalate on tissue levels and release of substance P in rat periaquaductal grey. Neuropeptides 28, 317-324.
42. Schmidt N.B., Storey J., Greenberg B.D., Santiago H.T., Li Q., Murphy D.L. Evaluating gene x psychological risk factor effects in the pathogenesis of anxiety: a new model approach. J. Abnorm. Psychol. 2000, 109:308-320.
43. Schruers K., Griez E. The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder. J. Psychopharmacol. 2004, 18:553-558.
44. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59:22-33.
45. Shlik J., Aluoja A., Vasar V., Vasar E., Podar T., Bradwejn J. Effects of citalopram treatment on behavioural, cardiovascular, and neuroendocrine responses to cholecystokinin tetrapeptide challenge in patients with panic disorder. J. Psychiatry Neurosci. 1997, 22:332-340.
46. Stahl S.M., Gergel I., Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2003, 64:1322-1327.
47. Townsend M.H., Conrad E.J. The therapeutic potential of escitalopram in the treatment of panic disorder. Neuropsychiatr. Dis. Treat. 2007, 3:835-838.
48. Tõru I., Shlik J., Maron E., Vasar V., Nutt D.J Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. Psychopharmacology 2006, 186:107-112.
49. Tõru I., Aluoja A., Võhma U., Raag M., Vasar V., Maron E., Shlik J. Associations between personality traits and CCK-4-induced panic attacks in healthy volunteers. Psychiatry Res. 2010, 178:342-347.
50. van Megen H.J.G.M., Westenberg H.G.M., den Boer J.A., Slaap B., Scheepmakers A. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology 1997, 129:357-364.
51. Zwanzger P., Baghai T.C., Schule C., Strohle A., Padberg F., Kathmann N., Schwarz M., Moller H.J., Rupprecht R. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4)-induced panic in healthy volunteers. Neuropsychopharmacology 2001, 25:699-703.
52. Zwanzger P., Eser D., Aicher S., Schule C., Baghai T.C., Padberg F., Ella R., Moller H.J., Rupprecht R. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. Neuropsychopharmacology 2003, 28:979-984.